ProCE Banner Series

Team Trivia! Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis

Join top dermatology experts at a live symposium on March 9 in Orlando, where cutting-edge insights on atopic dermatitis will be delivered through expert panels, real-time case discussions, and interactive case management voting via iPads. Earn your spot on the leaderboard in this fast-paced, team competition and enhance your clinical practice with the latest advancements in patient care.  Join in-person or virtually. Complimentary dinner and drinks for in-person attendees.

Who Should Attend

This education is intended for dermatologists, allergist/immunologists, and nurse practitioners (NPs) and physician associates (PAs) practicing in dermatology and allergy who manage patients with moderate to severe atopic dermatitis.

All Events

Team Trivia! Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis

Upcoming Events

March

09

2025

7:00 PM - 9:00 PM Eastern Time (ET)

In-person

Hilton Orlando, 6001 Destination Parkway, Orlando, Florida 32819

7:30 PM - 9:00 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this educational activity is to improve learners’ knowledge, competence, and performance managing advanced therapy for patients with moderate to severe atopic dermatitis.

Target Audience
This education is intended for dermatologists, allergist/immunologists, and nurse practitioners (NPs) and physician associates (PAs) practicing in dermatology and allergy who manage patients with moderate to severe atopic dermatitis.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Understand the pathophysiologic contributions of IL-13 in promoting the clinical manifestations of moderate to severe AD

  • Evaluate available evidence and current guidelines to differentiate advanced therapies targeting IL-13 in moderate to severe AD

  • Assess patient candidacy for advanced biologic therapies targeting IL-13 in moderate to severe AD

Accreditation

This educational activity is not certified for CME/CE credit.

Acknowledgement

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC and the National Eczema Association

This activity is supported by an educational grant from Lilly.